{"gene":"MSX2","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":1993,"finding":"A Pro148His substitution in the MSX2 homeodomain (position 7 of the N-terminal arm) causes autosomal dominant craniosynostosis (Boston type) by enhancing DNA binding affinity of the homeodomain, acting as a gain-of-function mutation.","method":"Human genetic mapping, segregation analysis, identification of missense mutation exclusively in affected individuals; mouse Msx2 transcript localization to calvarial sutures by in situ hybridization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutation identification with genetic segregation replicated and functionally validated in multiple subsequent studies","pmids":["8106171"],"is_preprint":false},{"year":1995,"finding":"Both wild-type and P148H mutant Msx2 specifically bind a high-affinity homeodomain DNA target and repress reporter gene transcription in a dose-dependent but DNA binding site-independent manner, establishing MSX2 as a transcriptional repressor.","method":"Co-transfection reporter assays in cell lines, EMSA/DNA-binding assays with recombinant proteins","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (EMSA + reporter assay) in a single study","pmids":["7726844"],"is_preprint":false},{"year":1996,"finding":"MSX-1 and MSX-2 share a common consensus DNA binding site but MSX-2 has higher apparent DNA-binding affinity; both function as transcriptional repressors independently of their consensus DNA binding sites; the distinction in repressor potency maps to sequences N-terminal to the homeodomain.","method":"DNA binding site selection, EMSA, luciferase reporter transcription assays with deletion mutants","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical assays (EMSA, reporter, deletion analysis), single lab","pmids":["8861098"],"is_preprint":false},{"year":1997,"finding":"The core suppressor domain of Msx2 maps to residues 97–208, with residues 132–148 (upstream of and overlapping the homeodomain N-terminal extension) being essential; transcriptional suppression of the osteocalcin promoter does not require direct DNA binding by Msx2. Msx2 binds both subunits of TFIIF (RAP74 and RAP30) through its core suppressor domain; overexpression of RAP74 partially reverses Msx2-mediated suppression.","method":"Systematic N- and C-terminal and internal deletion mutagenesis with luciferase reporter assays in MC3T3-E1 osteoblasts; Far-Western blotting with recombinant proteins; co-transfection rescue experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis, multiple orthogonal methods, functional validation in relevant cell type","pmids":["9265625"],"is_preprint":false},{"year":1997,"finding":"Msx2 suppresses FGF2/cAMP-stimulated but not calcitriol-stimulated osteocalcin promoter activity; mechanistically, Msx2 inhibits binding of the OCFRE-binding protein (OCFREB) to the FGF2-response element (OCFRE) via its core suppressor residues 132–148, without itself binding the OCFRE.","method":"Luciferase reporter assays in MC3T3-E1 osteoblasts with FGF2/forskolin or calcitriol stimulation; EMSA with recombinant GST-Msx2 and nuclear extracts; protein purification of OCFREB; deletion-mutant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified protein, mutagenesis, multiple orthogonal methods","pmids":["9368026"],"is_preprint":false},{"year":1997,"finding":"Miz1, a zinc-finger protein identified by yeast two-hybrid screen, directly interacts with Msx2 in vitro, enhances its DNA binding affinity for the osteocalcin promoter, and augments the effect of the P148H craniosynostosis mutation on DNA binding.","method":"Yeast two-hybrid screen, in vitro protein interaction assays, EMSA with Msx2 and Miz1, Northern blot and in situ hybridization for expression overlap","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus in vitro binding and EMSA, single lab","pmids":["9256341"],"is_preprint":false},{"year":1997,"finding":"Constitutive ectopic Msx2 expression induces apoptosis in aggregated P19 cells, and BMP4 induces cell death via an Msx2-dependent pathway; BMP4 treatment of P19 cells induces Msx2 transcription, placing Msx2 downstream of BMP4 in programmed cell death.","method":"Stable transfection of P19 cells with Msx2 expression construct; BMP4 treatment; apoptosis quantification; Msx2 mRNA induction assay","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function/gain-of-function with defined apoptosis phenotype, pathway positioning by BMP4-Msx2 epistasis, single lab","pmids":["9205134"],"is_preprint":false},{"year":1999,"finding":"MINT (Msx2-interacting nuclear target protein) was identified as a direct binding partner of Msx2; the interaction requires Msx2 residues necessary for transcriptional suppression; MINT's N-terminal RRM domain selectively binds the G/T-rich OCFRE in the osteocalcin promoter; MINT co-segregates with Msx2 in chromatin/nuclear matrix fractions.","method":"Far-Western expression cloning with radiolabeled GST-Msx2 fusion; Farwestern analysis; EMSA with MINT RRM domain; cellular fractionation and co-sedimentation with topoisomerase II; transient transfection reporter assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods including Far-Western, EMSA, fractionation, reporter assay, all in one rigorous study","pmids":["10451362"],"is_preprint":false},{"year":1999,"finding":"Overexpression of Msx2 in primary chick calvarial osteoblasts prevents osteoblast differentiation and matrix mineralization; antisense Msx2 decreases proliferation and accelerates differentiation; Msx2 promoter activity is downregulated in differentiating osteoblastic nodules, indicating Msx2 maintains osteoprogenitors in a proliferative, undifferentiated state.","method":"Retroviral-mediated sense and antisense Msx2 overexpression in primary calvarial osteoblasts; mineralization and differentiation marker assays; Msx2 promoter-reporter analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with defined cellular phenotype, single lab","pmids":["10328922"],"is_preprint":false},{"year":1999,"finding":"Msx2 gene dosage controls the number of proliferative osteogenic cells in calvarial sutures; tissue-specific Msx2 overexpression in suture mesenchymal cells enhances parietal bone growth and increases BrdU-labeling of osteoblastic cells at the osteogenic front, consistent with a transient retardation of osteogenic cell differentiation.","method":"Transgenic mouse overexpression with Msx2-specific suture promoter; BrdU proliferation assay; histological analysis of cranial sutures","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model with proliferation quantification, single lab","pmids":["9917362"],"is_preprint":false},{"year":2000,"finding":"Heterozygous loss-of-function mutations in the MSX2 homeodomain (RK159-160del and R172H) cause >85% reduction in DNA binding and produce parietal foramina via haploinsufficiency, demonstrating that MSX2 dosage is critical for calvarial ossification; in contrast, the gain-of-function P148H mutation that enhances DNA binding causes craniosynostosis.","method":"Human genetic mutation identification; in vitro DNA binding assays with mutant Msx2 proteins; mouse phenotype analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct DNA-binding biochemistry plus human genetics plus mouse phenotype, replicated across studies","pmids":["10742103"],"is_preprint":false},{"year":2000,"finding":"Msx2-deficient mice have defective proliferation of osteoprogenitors at the calvarial osteogenic front; Msx2 is required for both chondrogenesis and osteogenesis in axial and appendicular skeleton, operating downstream of Pth/Pthrp receptor signaling; Msx1/Msx2 genetic dosage interactions modify PFM phenotype, indicating functional overlap.","method":"Msx2 null mutant mouse phenotyping; BrdU labeling; in situ hybridization for marker genes; Msx1/Msx2 compound mutant analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse with defined cellular phenotype, BrdU proliferation assay, epistasis analysis, replicated across multiple tissues","pmids":["10742104"],"is_preprint":false},{"year":2002,"finding":"Pax3 represses Msx2 expression via a direct effect on a conserved Pax3-binding site in the Msx2 promoter; in Splotch (Pax3-null) mutant mice, upregulation of Msx2 causes the deficiency in cardiac neural crest development, establishing Msx2 as an immediate downstream effector of Pax3.","method":"Genetic epistasis (Splotch mutant × Msx2 mutant compound mice); molecular analysis of Pax3 binding to Msx2 promoter; in situ hybridization","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis plus direct promoter-binding evidence, multi-approach single lab","pmids":["11807043"],"is_preprint":false},{"year":2003,"finding":"Msx2 promotes osteogenic and suppresses adipogenic differentiation of mesenchymal progenitors; osteogenic actions require intrinsic DNA binding (gain-of-function P148H enhances mineralization; DNA-binding-deficient T147A is inactive for osteogenesis); suppression of adipogenesis does not require DNA binding but occurs via protein-protein interactions with C/EBPalpha controlling PPARgamma transcription.","method":"Viral transduction of Msx2 variants (wild-type, P148H, T147A) in C3H10T1/2 and aortic myofibroblast cells; alkaline phosphatase assay; mineralized nodule quantification; adipogenesis assays; C/EBPalpha interaction studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — structure-function mutagenesis distinguishing two mechanistic modes (DNA-binding-dependent vs. protein-protein interaction), multiple orthogonal readouts","pmids":["12925529"],"is_preprint":false},{"year":2003,"finding":"Smad4 and Lef1 cooperatively activate the Msx2 promoter in response to BMP2; Wnt/beta-catenin signaling activates Msx2 via Lef1 binding and synergizes with BMP2; Wnt-dependent Msx2 activation requires Smad4 (not Smad1) even in the absence of BMP autocrine loops, demonstrated by chromatin immunoprecipitation showing Smad4 in the Lef1 transcriptional complex.","method":"Msx2 promoter-reporter assays; mutagenesis of Smad-binding elements and Lef1/TCF sites; Smad4-deficient ES cells; chromatin immunoprecipitation; co-transfection with Smad1, Smad4, and Lef1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter dissection with mutagenesis, ChIP, genetic loss-of-function (Smad4-null cells), multiple orthogonal methods","pmids":["14551209"],"is_preprint":false},{"year":2004,"finding":"Msx2 occupies the osteocalcin gene promoter in proliferating (undifferentiated) osteoblasts and represses it; after proliferation, Msx2 is replaced by Dlx3, Dlx5, and Runx2, forming a molecular switch for osteocalcin transcriptional activation during osteoblast differentiation.","method":"Chromatin immunoprecipitation (ChIP) across stages of osteoblast differentiation; RNA interference knockdown of Dlx3; overexpression experiments; RNA polymerase II ChIP","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — sequential ChIP demonstrating temporal protein-DNA occupancy switch at endogenous locus across differentiation stages","pmids":["15456894"],"is_preprint":false},{"year":2004,"finding":"Msx2 suppresses BMP2-induced alkaline phosphatase (ALP) expression by competing with Dlx5 for the same cis-acting element in the ALP promoter; high Msx2 levels counteract Dlx5-stimulated ALP transcription until the Dlx5:Msx2 ratio exceeds a threshold.","method":"ALP promoter dissection with EMSA and site-directed mutagenesis; Msx2 overexpression in C2C12 and Runx2(-/-) cells; ALP mRNA and enzyme activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter mutagenesis, EMSA demonstrating competitive binding, functional reporter assay, single lab","pmids":["15383550"],"is_preprint":false},{"year":2004,"finding":"Msx2 colocalizes with Runx2/Osf2 and suppresses Runx2 transcriptional activity cooperatively with TLE1, recruiting HDAC1 activity to inhibit osteoblast differentiation in ligament fibroblasts; stable Msx2 knockdown in PDL-L2 cells induces osteoblastic differentiation and matrix mineralization.","method":"Co-immunoprecipitation; co-localization studies; RNA interference; stable overexpression in MC3T3-E1 cells; in situ hybridization; RT-PCR","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, loss-of-function and gain-of-function with defined mineralization phenotype, HDAC recruitment assay","pmids":["15060165"],"is_preprint":false},{"year":2004,"finding":"MINT interacts functionally with Runx2 to enhance OCFRE-driven osteocalcin transcription; Msx2 abrogates Runx2-MINT activation by selectively inhibiting Runx2 binding to OC chromatin (demonstrated by ChIP); MINT adopts a reticular nuclear matrix distribution co-localizing with phospho-RNA polymerase II.","method":"Luciferase reporter assays in MC3T3E1 and CV1 cells; confocal immunofluorescence microscopy; chromatin immunoprecipitation; MINT RNA interference","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP showing Msx2 inhibits Runx2 chromatin binding, confocal localization, reporter reconstitution, multiple methods","pmids":["15131132"],"is_preprint":false},{"year":2004,"finding":"Necdin associates with Msx2 via MAGE-D1; a ternary complex of necdin, MAGE-D1, and Msx2 forms in vitro and is detected as an endogenous complex in differentiating embryonal carcinoma cells; co-expression of necdin and MAGE-D1 relieves Msx2-dependent transcriptional repression and rescues Msx2-inhibited myogenic differentiation in C2C12 cells.","method":"In vitro binding assays; co-immunoprecipitation; stable transfection of C2C12 with Msx2; rescue co-expression experiments; differentiation marker assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro binding, endogenous Co-IP, functional rescue, multiple orthogonal methods in one study","pmids":["15272023"],"is_preprint":false},{"year":2004,"finding":"Msx2 inhibits transcriptional activity of PPARgamma, C/EBPbeta, and C/EBPdelta, blocking adipocyte differentiation induced by overexpression of each; and promotes osteoblast differentiation independently of Runx2 (active in Runx2-null cells).","method":"Overexpression and reporter assays in C3H10T1/2, C2C12, 3T3-F442A, and Runx2(-/-) mesenchymal cells; alkaline phosphatase and adipogenesis assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell line contexts, multiple differentiation readouts, single lab","pmids":["15175325"],"is_preprint":false},{"year":2005,"finding":"Msx2-expressing cells secrete paracrine Wnt signals (upregulating Wnt3a and Wnt7a, downregulating Dkk1) that promote osteogenic and suppress adipogenic differentiation; Msx2 induces nuclear beta-catenin accumulation and TCF/LEF transcriptional activity; Dkk1 treatment reverses these effects; in vivo, TOPGAL reporter mice confirm augmented Wnt signaling in Msx2-transgenic aorta.","method":"Conditioned media transfer experiments; TCF/LEF reporter (TOPGAL) transgenic mice; immunofluorescence for nuclear beta-catenin; alkaline phosphatase assay; Dkk1 rescue; qRT-PCR for Wnt ligands","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditioned media, in vivo reporter mouse, multiple orthogonal methods, mechanistic rescue with Dkk1","pmids":["15841209"],"is_preprint":false},{"year":2006,"finding":"Msx1 and Msx2 form a ternary complex with SRF and myocardin, inhibiting SRF/myocardin binding to the CArG-box motif and suppressing smooth muscle cell marker gene (SM22alpha, caldesmon) transcription; this interaction is induced downstream of BMP2/4/6 signaling.","method":"Co-immunoprecipitation; gel-shift (EMSA); chromatin immunoprecipitation; promoter-reporter assays; BMP treatment of VSMCs","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP, EMSA, ChIP, and reporter assay demonstrating ternary complex inhibiting CArG-box binding","pmids":["17030628"],"is_preprint":false},{"year":2007,"finding":"Msx2 is a direct transcriptional target of Notch/RBP-Jk signaling; Notch1 intracellular domain (N1-ICD) induces Msx2 gene expression via an RBP-Jk-binding element within the Msx2 promoter; RBP-Jk-deficient cells fail to induce Msx2 in response to N1-ICD; Msx2 mediates N1-ICD-induced ALP activity and vascular smooth muscle cell mineralization.","method":"Msx2 promoter deletion and site-directed mutagenesis; RBP-Jk-deficient fibroblasts; siRNA knockdown of Msx2 and RBP-Jk; ALP activity assay; immunohistochemistry of human calcifying plaques","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter mutagenesis plus genetic loss-of-function (RBP-Jk-null cells) plus siRNA, three orthogonal approaches","pmids":["19407244"],"is_preprint":false},{"year":2007,"finding":"Vitamin K2 (MK4) activates Msx2 gene transcription through PXR binding to a PXRE in the Msx2 promoter; ChIP shows PXR and p300 coactivator recruitment to this element; MK4-bound PXR cooperates with estrogen-bound ERalpha on the Msx2 promoter; knockdown of PXR or Msx2 attenuates MK4-induced osteoblast differentiation.","method":"2D-SDS-PAGE proteomics; Msx2 promoter reporter mapping; ChIP for PXR and p300; siRNA knockdown; co-transfection of PXR/RXRalpha/ERalpha","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP plus promoter mapping plus siRNA, multiple orthogonal methods establishing PXR as direct Msx2 transcriptional activator","pmids":["17875939"],"is_preprint":false},{"year":2008,"finding":"BMP2 regulates Osterix via two parallel pathways: a Runx2-dependent pathway and a Runx2-independent pathway through Msx2; Msx2 (induced by BMP2 in Runx2-null cells via Smad1/Smad4) induces Osterix expression; Msx2 knockdown inhibits BMP2-induced Osterix in Runx2-null cells.","method":"Runx2-deficient mesenchymal cells; Msx2 overexpression and siRNA knockdown; BMP2 treatment; Osterix and ALP expression assays; Smad overexpression/inhibitory Smad experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — Runx2-null genetic background clarifies pathway, gain and loss of function, multiple readouts, single lab with strong controls","pmids":["18703512"],"is_preprint":false},{"year":2008,"finding":"Msx2 exerts bone anabolic effects by reducing Dkk1 expression and enhancing canonical Wnt (Wnt7a, Wnt7b) signaling; Msx2 inhibits Dkk1 promoter activity and reduces RNA polymerase II association with Dkk1 chromatin; RNAi knockdown of Wnt7a, Wnt7b, and LRP6 significantly reduces Msx2-induced alkaline phosphatase; confirmed in Msx2-transgenic mice using TOPGAL reporter.","method":"CMV-Msx2 transgenic mice; microCT; histomorphometry; TOPGAL Wnt reporter; Msx2 siRNA; ChIP for RNA Pol II at Dkk1; Wnt7a/7b/LRP6 knockdown with rescue assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic with TOPGAL reporter, ChIP, systematic siRNA epistasis, multiple orthogonal methods","pmids":["18487199"],"is_preprint":false},{"year":2008,"finding":"Msx1 and Msx2 bind cardiac T-box proteins Tbx2, Tbx3, and Tbx5 via their homeodomain and T-box domains; Msx proteins together with Tbx2/Tbx3 suppress Connexin43 (Cx43) promoter activity; Msx1 binds the Cx43 promoter at a conserved site adjacent to a T-box site (by ChIP), and Msx activity on the Cx43 promoter depends on the presence of Tbx3.","method":"Yeast two-hybrid screen; in vitro pull-down; reporter assays in rat heart-derived cells; chromatin immunoprecipitation","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid plus pulldown plus ChIP plus reporter assay, multiple orthogonal methods","pmids":["18285513"],"is_preprint":false},{"year":2008,"finding":"Msx2 promotes chondrocyte maturation in part by upregulating Ihh (Indian hedgehog) expression; cyclopamine (hedgehog pathway inhibitor) blocks Msx2-induced chondrogenesis; Msx2's chondrogenic action requires BMP2/Smad signaling (Smad1/4 enhance, Smad6 blocks).","method":"Overexpression of constitutively active Msx2 in primary chondrocytes and metatarsal explants; cyclopamine treatment; Smad overexpression/inhibition; ALP and collagen X expression assays; Msx2 siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with pharmacological rescue, single lab, multiple assays","pmids":["18682398"],"is_preprint":false},{"year":2008,"finding":"The Boston craniosynostosis P148H mutation renders MSX2 more susceptible to ubiquitin-dependent proteasomal degradation; Praja1 E3 ubiquitin ligase mediates MSX2 degradation; P148H shows greater ubiquitylation and shorter protein half-life than wild-type; P148H functions as a dominant-negative by increasing ubiquitylation of wild-type MSX2.","method":"Pulse-chase protein half-life experiments; ubiquitylation assays; Praja1 co-expression; dominant-negative co-expression; osteoblast proliferation and cyclin D1 assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — pulse-chase, ubiquitylation assay, E3 ligase identification, dominant-negative mechanism, multiple orthogonal methods","pmids":["18786927"],"is_preprint":false},{"year":2008,"finding":"BMP4-induced EMT in pancreatic cancer cells requires MSX2; BMP4 induces MSX2 via ERK, p38 MAPK, and Smad pathways; siRNA-mediated MSX2 knockdown abolishes BMP4-induced E-cadherin repression, vimentin induction, and enhanced cell migration.","method":"BMP4 treatment of Panc-1 cells; MSX2 siRNA knockdown; pathway inhibitors (ERK, p38, Smad); migration assays; Western blot for EMT markers","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis plus pathway inhibitor rescue, single lab, multiple EMT readouts","pmids":["17516553"],"is_preprint":false},{"year":2010,"finding":"Msx2 mediates TNF-alpha inhibition of BMP2-induced osteoblast differentiation; TNF-alpha induces Msx2 via NF-kappaB pathway (not JNK); Msx2 siRNA rescues ALP expression suppressed by TNF-alpha, placing Msx2 as a downstream effector of TNF-alpha/NF-kappaB in inhibiting osteogenesis.","method":"TNF-alpha treatment of C2C12 and Runx2(-/-) calvarial cells; pathway-specific inhibitors for NF-kappaB and JNK; Msx2 siRNA knockdown; ALP expression assays","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis plus pharmacological pathway inhibitors, single lab","pmids":["20440096"],"is_preprint":false},{"year":2011,"finding":"TNF acts through TNFR1 (not TNFR2) to upregulate Msx2 via reactive oxygen species (ROS) generated by NADPH oxidase (Nox); hydrogen peroxide directly upregulates Msx2 mRNA and promoter activity; Nox inhibition, p47phox genetic deficiency, and rotenone reduce TNF-induced Msx2; TNFR1-null aortic myofibroblasts express ~5% of wild-type Msx2 and are non-inducible by TNF.","method":"TNFR1-/- and TNFR2-/- cells; p47phox-/- cells; Nox inhibitors; H2O2 treatment; Msx2 promoter reporter; antisense oligonucleotides in SM22-TNF transgenic mice","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic knockouts, pharmacological inhibition, reporter assay, in vivo validation, orthogonal approaches","pmids":["22685265"],"is_preprint":false},{"year":2011,"finding":"Notch signaling (N1-ICD/RBP-Jk) enhances BMP2-responsiveness of the Msx2 promoter; Smad1 interacts with N1-ICD to form a complex within the Msx2 promoter; RBP-Jk binding element is required for this synergistic BMP2 + Notch induction of Msx2 gene expression and subsequent ALP activity/mineralization in smooth muscle cells.","method":"Msx2 promoter deletion/mutation analysis; RBP-Jk-deficient cells; siRNA for RBP-Jk; co-immunoprecipitation of Smad1 and N1-ICD; ChIP at Msx2 promoter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter mutagenesis, genetic loss-of-function (RBP-Jk null), Co-IP demonstrating Smad1-N1-ICD complex on Msx2 promoter, ChIP","pmids":["21471203"],"is_preprint":false},{"year":2012,"finding":"MSX2 directly regulates ABCG2 transcription in functional cooperation with SP1 via SP1-binding elements within the ABCG2 promoter; MSX2 overexpression or siRNA knockdown proportionally changes ABCG2 expression, and MSX2 expression correlates with chemoresistance.","method":"ABCG2 promoter reporter assay with MSX2 and SP1 co-expression; siRNA knockdown; overexpression; correlation of MSX2 and ABCG2 mRNA levels across cell lines","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter plus gain/loss-of-function, single lab","pmids":["21465479"],"is_preprint":false},{"year":2012,"finding":"FOXC1 directly occupies a conserved element in the MSX2 promoter (by ChIP) and transcriptionally activates both human and mouse MSX2 promoters; FOXC1 siRNA reduces endogenous MSX2 expression; heterologous Foxc1 expression in C2C12 cells elevates ALP activity and Runx2 and Msx2 levels, placing FOXC1 upstream of MSX2 in early osteoblast differentiation.","method":"ChIP for FOXC1 at MSX2 promoter; luciferase reporter assays; siRNA; Foxc1 overexpression in C2C12","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus siRNA, single lab","pmids":["23145080"],"is_preprint":false},{"year":2013,"finding":"Msx2 and Wnt7b signaling maintain aortic endothelial cell (EC) phenotype and oppose endothelial-mesenchymal transition (EndoMT); EC-specific deletion of Wnt7b upregulates osteogenic genes including Msx2 and nuclear phospho-Smad1/5; Msx2 in ECs has the opposite effect to mesenchymal cells, preserving EC identity.","method":"Cdh5-Cre;Wnt7b(fl/fl);LDLR(-/-) conditional knockout mice; adenoviral transduction of aortic ECs; immunofluorescence; Western blot; calcium/collagen quantification","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional EC-specific knockout with defined phenotype, single lab","pmids":["23685555"],"is_preprint":false},{"year":2015,"finding":"MSX2 is a direct BMP pathway target in human pluripotent stem cells (hPSCs); MSX2 destabilizes pluripotency by directly binding the SOX2 promoter and repressing SOX2 transcription; simultaneously MSX2 directly activates Nodal promoter to commit cells to mesendoderm; SOX2 can promote MSX2 protein degradation, establishing mutual antagonism; Wnt signals via LEF1 synergistically activate MSX2 during mesendoderm induction.","method":"MSX2 overexpression and shRNA depletion in hPSCs; ChIP for MSX2 binding to SOX2 and Nodal promoters; promoter reporter assays; protein half-life measurement; MSX2/SOX2 co-expression","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP for direct promoter binding plus gain/loss-of-function, mutual protein-level antagonism demonstrated, multiple targets and mechanisms","pmids":["26427715"],"is_preprint":false},{"year":2019,"finding":"MSX2 is a substrate of FBXW2 E3 ubiquitin ligase; FBXW2 binds MSX2, promotes its ubiquitylation and proteasomal degradation, and shortens its protein half-life; hypoxia induces VRK2 kinase to facilitate MSX2-FBXW2 binding and enhance FBXW2-mediated MSX2 degradation; MSX2 accumulation (upon FBXW2 inactivation) represses SOX2 transcription.","method":"Co-immunoprecipitation; ubiquitylation assays; FBXW2 overexpression and siRNA knockdown with pulse-chase; VRK2 kinase assays; in vitro and in vivo breast cancer models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP, ubiquitylation assay, pulse-chase, kinase assay, in vivo validation, multiple orthogonal methods","pmids":["31548378"],"is_preprint":false},{"year":2021,"finding":"MSX2 represses the syncytiotrophoblast transcriptional program in human trophoblast stem cells; MSX2 directly binds and regulates differentiation genes; MSX2 interacts with the SWI/SNF canonical BAF (cBAF) subcomplex and co-occupies target genes together with H3K27ac; MSX2 depletion increases H3K27ac and cBAF occupancy at differentiation genes, indicating MSX2 prevents chromatin remodeling at syncytiotrophoblast loci.","method":"MSX2 shRNA depletion and overexpression in human trophoblast stem cells; ChIP-seq for MSX2, H3K27ac, and cBAF components; immunoprecipitation-mass spectrometry for MSX2 interactors; transcriptomics","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-seq for direct binding, MS-identified complex, gain/loss-of-function, multiple orthogonal genome-wide methods","pmids":["34507999"],"is_preprint":false},{"year":2023,"finding":"CLU-mediated mitophagy promotes degradation of MSX2 in mitochondria/cytoplasm, preventing its nuclear translocation; when MSX2 is degraded by mitophagy, SOX2 expression is derepressed, maintaining cancer stemness; CLU activates AKT, which phosphorylates DNM1L/Drp1 at Ser616 to initiate mitochondrial fission preceding mitophagy of MSX2.","method":"CLU gain/loss-of-function in oral CSCs; MSX2 nuclear vs. cytoplasmic fractionation; mitophagy assays; AKT inhibition; DNM1L phosphorylation assays; SOX2 reporter/expression assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation demonstrating mitophagy-dependent nuclear exclusion, AKT-DNM1L pathway, single lab","pmids":["36779631"],"is_preprint":false}],"current_model":"MSX2 is a homeodomain transcriptional repressor that controls osteogenic, adipogenic, chondrogenic, and cell fate decisions downstream of BMP2/4/Smad, Wnt/beta-catenin, Notch/RBP-Jk, TNF/TNFR1/ROS, and FGF signaling; it represses gene transcription through a core suppressor domain (residues 97–208, critical residues 132–148) via protein-protein interactions with TFIIF (RAP74), Runx2 (recruiting TLE1/HDAC1), MINT, myocardin/SRF, C/EBPalpha, and the cBAF SWI/SNF complex, largely independently of direct DNA binding; promotes osteogenesis in part by suppressing Dkk1 and upregulating Wnt7a/Wnt7b for paracrine Wnt signaling; its protein stability is regulated by FBXW2-mediated ubiquitylation/proteasomal degradation (enhanced by VRK2-facilitated FBXW2 binding) and by mitophagic degradation downstream of CLU/AKT/DNM1L; gain-of-function (P148H) causes craniosynostosis by enhancing DNA-binding affinity while also increasing proteasomal susceptibility, and haploinsufficiency causes parietal foramina, demonstrating strict dosage requirements for calvarial morphogenesis."},"narrative":{"mechanistic_narrative":"MSX2 is a homeodomain transcriptional repressor that acts as a dosage-sensitive node integrating BMP, Wnt, Notch, FGF, and TNF signals to control osteogenic, adipogenic, chondrogenic, and broader cell-fate decisions [PMID:12925529, PMID:15841209, PMID:19407244]. It represses transcription largely independently of direct DNA binding through a core suppressor domain (residues 97–208, with residues 132–148 essential) that engages the basal machinery and other regulators: it binds both subunits of TFIIF (RAP74/RAP30) [PMID:9265625], blocks promoter occupancy of partner factors such as the OCFRE-binding protein and Runx2 [PMID:9368026, PMID:15131132], and cooperates with TLE1 to recruit HDAC1 to suppress Runx2-driven osteoblast differentiation [PMID:15060165]. MSX2 maintains osteoprogenitors in a proliferative, undifferentiated state—occupying the osteocalcin promoter until it is replaced by Dlx/Runx2 as a differentiation switch [PMID:15456894]—and competes with Dlx5 and inhibits adipogenic factors PPARγ and C/EBPα through protein–protein interaction, biasing mesenchymal progenitors toward bone over fat [PMID:12925529, PMID:15383550, PMID:15175325]. Its bone-anabolic output is amplified by paracrine canonical Wnt signaling: MSX2 represses Dkk1 and induces Wnt7a/Wnt7b to drive β-catenin/TCF activity [PMID:15841209, PMID:18487199]. Beyond the skeleton, MSX2 represses pluripotency and lineage programs by directly binding promoters—repressing SOX2 while activating Nodal in mesendoderm commitment [PMID:26427715]—and prevents cBAF-dependent chromatin remodeling at syncytiotrophoblast differentiation genes [PMID:34507999]. MSX2 protein abundance is tightly controlled by FBXW2-mediated ubiquitin–proteasomal degradation, enhanced by hypoxia-induced VRK2, and by CLU/AKT/DNM1L-driven mitophagic clearance that excludes it from the nucleus to derepress SOX2 [PMID:31548378, PMID:36779631]. Gain-of-function P148H enhances homeodomain DNA-binding affinity to cause Boston-type craniosynostosis while paradoxically increasing proteasomal susceptibility, and homeodomain loss-of-function mutations cause parietal foramina by haploinsufficiency, establishing strict gene-dosage requirements for calvarial morphogenesis [PMID:8106171, PMID:10742103, PMID:18786927].","teleology":[{"year":1993,"claim":"Established MSX2 as a disease gene by linking a homeodomain point mutation to a calvarial malformation, framing the question of how a transcription factor controls suture morphogenesis.","evidence":"Human genetic mapping and segregation of the P148H missense allele, with mouse calvarial in situ localization","pmids":["8106171"],"confidence":"High","gaps":["Did not establish the molecular mechanism of repression","Left open how enhanced DNA binding translates to premature suture fusion"]},{"year":1996,"claim":"Defined MSX2's biochemical activity as a transcriptional repressor that acts independently of its consensus DNA-binding site, with repressor potency mapping outside the homeodomain.","evidence":"DNA-binding site selection, EMSA, and luciferase reporter assays with deletion mutants in cell lines","pmids":["7726844","8861098"],"confidence":"Medium","gaps":["Did not identify the protein partners mediating DNA-binding-independent repression","Endogenous target genes not defined"]},{"year":1997,"claim":"Mapped the core suppressor domain and identified its first mechanistic basis—engagement of the basal transcription factor TFIIF—explaining DNA-binding-independent repression.","evidence":"Systematic deletion mutagenesis with osteoblast reporter assays, Far-Western binding, and RAP74 rescue, plus blocking of OCFREB binding to the FGF-response element","pmids":["9265625","9368026"],"confidence":"High","gaps":["Did not show TFIIF interaction at endogenous loci by ChIP","Did not establish which signaling inputs deploy the suppressor domain"]},{"year":1999,"claim":"Identified nuclear protein partners (MINT, Miz1) and positioned MSX2 as a brake on osteoblast differentiation that keeps progenitors proliferative.","evidence":"Far-Western expression cloning, yeast two-hybrid, EMSA, fractionation, and reciprocal gain/loss-of-function in calvarial osteoblasts","pmids":["10451362","9256341","10328922"],"confidence":"High","gaps":["Interaction stoichiometry and complex architecture unresolved","Whether MINT and Miz1 act on the same target promoters not tested"]},{"year":2000,"claim":"Resolved the dosage logic of MSX2 in the skull by contrasting gain-of-function craniosynostosis with loss-of-function parietal foramina.","evidence":"Human mutation identification with in vitro DNA-binding assays and Msx2-null mouse phenotyping including BrdU and epistasis with Msx1","pmids":["10742103","10742104"],"confidence":"High","gaps":["Direct transcriptional targets governing osteoprogenitor proliferation not enumerated","Mechanism of Msx1/Msx2 functional redundancy at the molecular level unclear"]},{"year":2003,"claim":"Distinguished two mechanistic modes of MSX2 action—DNA-binding-dependent pro-osteogenic versus protein-interaction-dependent anti-adipogenic—and placed it downstream of BMP2/Wnt via Smad4/Lef1 promoter activation.","evidence":"Structure-function mutagenesis (P148H, T147A) in mesenchymal cells, C/EBPα interaction studies, and Msx2 promoter dissection with ChIP in Smad4-null cells","pmids":["12925529","14551209"],"confidence":"High","gaps":["How a single protein switches between the two modes in vivo not defined","Direct osteogenic DNA targets requiring binding not identified"]},{"year":2004,"claim":"Defined MSX2 as the repressive arm of a temporal molecular switch at osteoblast promoters, acting via competition with Dlx5/Runx2 and recruitment of TLE1/HDAC1.","evidence":"Stage-resolved ChIP at osteocalcin, EMSA competition at the ALP promoter, Co-IP and HDAC recruitment assays, and ternary complexes with necdin/MAGE-D1 and Runx2/MINT","pmids":["15456894","15383550","15060165","15131132","15175325","15272023"],"confidence":"High","gaps":["Quantitative thresholds for the Dlx5:Msx2 switch in vivo not established","Generality of HDAC1/TLE1 recruitment across MSX2 targets untested"]},{"year":2005,"claim":"Showed MSX2 acts non-cell-autonomously through secreted Wnt ligands and Dkk1 repression to bias mesenchymal fate toward bone.","evidence":"Conditioned media transfer, TOPGAL reporter mice, nuclear β-catenin imaging, and Dkk1 rescue","pmids":["15841209"],"confidence":"High","gaps":["Whether Wnt ligand induction is direct transcriptional activation by MSX2 not shown here","Receiving cell populations in vivo not fully defined"]},{"year":2008,"claim":"Expanded MSX2's regulatory inputs (Notch/RBP-Jk, PXR, BMP2/Smad in Runx2-null context) and outputs (Osterix, Ihh, smooth-muscle and cardiac genes), and revealed proteasomal control of the protein.","evidence":"Promoter mutagenesis with RBP-Jk-null cells, ChIP for PXR/p300, Runx2-null epistasis for Osterix, T-box partner pulldowns, and pulse-chase/ubiquitylation with Praja1 E3 ligase","pmids":["19407244","17875939","18703512","18682398","18285513","17030628","18786927","17516553"],"confidence":"High","gaps":["How distinct upstream signals select between activation and repression outputs unresolved","Physiological relevance of Praja1-mediated turnover in vivo not established"]},{"year":2011,"claim":"Defined a TNF→TNFR1→Nox/ROS axis driving MSX2 to inhibit osteogenesis and demonstrated Notch–BMP synergy at the MSX2 promoter via a Smad1–N1ICD complex.","evidence":"TNFR1/TNFR2 and p47phox knockouts, Nox inhibitors, H2O2 promoter assays, and Co-IP/ChIP at the Msx2 promoter","pmids":["22685265","21471203","20440096"],"confidence":"High","gaps":["Downstream osteogenic targets repressed by ROS-induced MSX2 not enumerated","Cell-type specificity of the ROS input not generalized"]},{"year":2015,"claim":"Generalized MSX2 to stem-cell fate control as a direct repressor of SOX2 and activator of Nodal, establishing mutual MSX2–SOX2 antagonism at both transcript and protein levels.","evidence":"ChIP for direct promoter binding, gain/loss-of-function in hPSCs, and protein half-life measurements","pmids":["26427715"],"confidence":"High","gaps":["Co-factors at the SOX2 and Nodal promoters not identified","Mechanism of SOX2-driven MSX2 protein destabilization unresolved"]},{"year":2021,"claim":"Connected MSX2 repression to chromatin remodeling control, showing it restrains cBAF/H3K27ac at differentiation loci, and identified cBAF as a physical interactor.","evidence":"ChIP-seq for MSX2/H3K27ac/cBAF, IP-MS for interactors, and gain/loss-of-function in human trophoblast stem cells","pmids":["34507999"],"confidence":"High","gaps":["Whether MSX2 directly antagonizes cBAF recruitment or via intermediaries not resolved","Generality of cBAF antagonism beyond trophoblast loci untested"]},{"year":2023,"claim":"Established a second post-translational control layer: mitophagic degradation of MSX2 via CLU/AKT/DNM1L excludes it from the nucleus to derepress SOX2 and sustain cancer stemness.","evidence":"CLU gain/loss-of-function, nuclear/cytoplasmic fractionation, mitophagy assays, AKT inhibition and DNM1L phosphorylation assays in oral cancer stem cells","pmids":["36779631"],"confidence":"Medium","gaps":["How nuclear MSX2 is routed to mitochondria for mitophagy mechanistically unclear","Single-lab finding awaiting independent confirmation"]},{"year":null,"claim":"It remains unresolved how MSX2 dynamically selects between its repressor and activator outputs and between DNA-binding-dependent and -independent modes in response to distinct upstream signals at the level of a unified molecular mechanism.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of MSX2 bound to its co-repressors or to cBAF","Genome-wide direct target catalogs across lineages incomplete","Integration of transcriptional inputs with FBXW2/VRK2 and mitophagy degradation control not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,3,13,15,37,39]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,10,13,37]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[37,39]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,18,40]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[40]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,13,15,37,39]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,21,23,26,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,13,28,37]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[29,38]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[17,39]}],"complexes":["cBAF (SWI/SNF)"],"partners":["RAP74 (GTF2F1)","RUNX2","TLE1","HDAC1","MINT (SPEN)","C/EBPALPHA","MYOCARDIN","FBXW2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35548","full_name":"Homeobox protein MSX-2","aliases":["Homeobox protein Hox-8"],"length_aa":267,"mass_kda":28.9,"function":"Acts as a transcriptional regulator in bone development. Represses the ALPL promoter activity and antagonizes the stimulatory effect of DLX5 on ALPL expression during osteoblast differentiation. Probable morphogenetic role. May play a role in limb-pattern formation. In osteoblasts, suppresses transcription driven by the osteocalcin FGF response element (OCFRE). Binds to the homeodomain-response element of the ALPL promoter","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P35548/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MSX2","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MSX2","total_profiled":1310},"omim":[{"mim_id":"613484","title":"SPEN FAMILY TRANSCRIPTIONAL REPRESSOR; SPEN","url":"https://www.omim.org/entry/613484"},{"mim_id":"609675","title":"SCLEROSTIN DOMAIN-CONTAINING PROTEIN 1; SOSTDC1","url":"https://www.omim.org/entry/609675"},{"mim_id":"609597","title":"PARIETAL FORAMINA 2; PFM2","url":"https://www.omim.org/entry/609597"},{"mim_id":"608279","title":"CRANIOSYNOSTOSIS WITH OCULAR ABNORMALITIES AND HALLUCAL DEFECTS","url":"https://www.omim.org/entry/608279"},{"mim_id":"606529","title":"CRANIOSYNOSTOSIS SYNDROME, AUTOSOMAL RECESSIVE","url":"https://www.omim.org/entry/606529"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"parathyroid gland","ntpm":24.2},{"tissue":"placenta","ntpm":31.5},{"tissue":"urinary bladder","ntpm":16.3}],"url":"https://www.proteinatlas.org/search/MSX2"},"hgnc":{"alias_symbol":["CRS2","FPP","HOX8","MSH","PFM"],"prev_symbol":["PFM1"]},"alphafold":{"accession":"P35548","domains":[{"cath_id":"1.10.10.60","chopping":"149-212","consensus_level":"medium","plddt":96.6245,"start":149,"end":212}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35548","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35548-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35548-F1-predicted_aligned_error_v6.png","plddt_mean":67.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MSX2","jax_strain_url":"https://www.jax.org/strain/search?query=MSX2"},"sequence":{"accession":"P35548","fasta_url":"https://rest.uniprot.org/uniprotkb/P35548.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35548/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35548"}},"corpus_meta":[{"pmid":"10742104","id":"PMC_10742104","title":"Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10742104","citation_count":598,"is_preprint":false},{"pmid":"8106171","id":"PMC_8106171","title":"A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8106171","citation_count":563,"is_preprint":false},{"pmid":"18703512","id":"PMC_18703512","title":"BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18703512","citation_count":427,"is_preprint":false},{"pmid":"15841209","id":"PMC_15841209","title":"Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15841209","citation_count":365,"is_preprint":false},{"pmid":"12925529","id":"PMC_12925529","title":"MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12925529","citation_count":282,"is_preprint":false},{"pmid":"17932314","id":"PMC_17932314","title":"Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17932314","citation_count":268,"is_preprint":false},{"pmid":"1358591","id":"PMC_1358591","title":"Expression patterns of the homeobox gene, Hox-8, in the mouse embryo suggest a role in specifying tooth initiation and shape.","date":"1992","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1358591","citation_count":268,"is_preprint":false},{"pmid":"15456894","id":"PMC_15456894","title":"Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15456894","citation_count":230,"is_preprint":false},{"pmid":"10742103","id":"PMC_10742103","title":"Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10742103","citation_count":229,"is_preprint":false},{"pmid":"14551209","id":"PMC_14551209","title":"Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14551209","citation_count":173,"is_preprint":false},{"pmid":"12750290","id":"PMC_12750290","title":"Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12750290","citation_count":165,"is_preprint":false},{"pmid":"15383550","id":"PMC_15383550","title":"Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by Dlx5 and repressed by Msx2.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15383550","citation_count":163,"is_preprint":false},{"pmid":"9917362","id":"PMC_9917362","title":"Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: a possible mechanism for MSX2-mediated craniosynostosis in humans.","date":"1999","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9917362","citation_count":157,"is_preprint":false},{"pmid":"8787747","id":"PMC_8787747","title":"Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8787747","citation_count":155,"is_preprint":false},{"pmid":"16221730","id":"PMC_16221730","title":"Combined deficiencies of Msx1 and Msx2 cause impaired patterning and survival of the cranial neural crest.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16221730","citation_count":154,"is_preprint":false},{"pmid":"14597577","id":"PMC_14597577","title":"Msx2 and Twist cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14597577","citation_count":153,"is_preprint":false},{"pmid":"15175325","id":"PMC_15175325","title":"Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15175325","citation_count":152,"is_preprint":false},{"pmid":"8106021","id":"PMC_8106021","title":"Expression of homeobox genes Msx-1 (Hox-7) and Msx-2 (Hox-8) during cardiac development in the chick.","date":"1993","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/8106021","citation_count":143,"is_preprint":false},{"pmid":"9205134","id":"PMC_9205134","title":"Msx2 is a transcriptional regulator in the BMP4-mediated programmed cell death pathway.","date":"1997","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9205134","citation_count":131,"is_preprint":false},{"pmid":"12466204","id":"PMC_12466204","title":"'Cyclic alopecia' in Msx2 mutants: defects in hair cycling and hair shaft differentiation.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12466204","citation_count":123,"is_preprint":false},{"pmid":"18056036","id":"PMC_18056036","title":"Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification.","date":"2007","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18056036","citation_count":119,"is_preprint":false},{"pmid":"8861098","id":"PMC_8861098","title":"Comparison of MSX-1 and MSX-2 suggests a molecular basis for functional redundancy.","date":"1996","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/8861098","citation_count":117,"is_preprint":false},{"pmid":"15930102","id":"PMC_15930102","title":"Analysis of Msx1; Msx2 double mutants reveals multiple roles for Msx genes in limb development.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15930102","citation_count":114,"is_preprint":false},{"pmid":"17693062","id":"PMC_17693062","title":"Concerted action of Msx1 and Msx2 in regulating cranial neural crest cell differentiation during frontal bone development.","date":"2007","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/17693062","citation_count":110,"is_preprint":false},{"pmid":"10328922","id":"PMC_10328922","title":"Ectopic Msx2 overexpression inhibits and Msx2 antisense stimulates calvarial osteoblast differentiation.","date":"1999","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10328922","citation_count":100,"is_preprint":false},{"pmid":"9578615","id":"PMC_9578615","title":"Ectopic expression of Msx-2 in posterior limb bud mesoderm impairs limb morphogenesis while inducing BMP-4 expression, inhibiting cell proliferation, and promoting apoptosis.","date":"1998","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9578615","citation_count":100,"is_preprint":false},{"pmid":"9846383","id":"PMC_9846383","title":"Expression of Msx-2 during development, regeneration, and wound healing in axolotl limbs.","date":"1998","source":"The Journal of experimental zoology","url":"https://pubmed.ncbi.nlm.nih.gov/9846383","citation_count":100,"is_preprint":false},{"pmid":"23685555","id":"PMC_23685555","title":"Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23685555","citation_count":97,"is_preprint":false},{"pmid":"9147639","id":"PMC_9147639","title":"Perinatal lethality and multiple craniofacial malformations in MSX2 transgenic mice.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9147639","citation_count":96,"is_preprint":false},{"pmid":"10767084","id":"PMC_10767084","title":"Positionally-dependent chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10767084","citation_count":91,"is_preprint":false},{"pmid":"31548378","id":"PMC_31548378","title":"The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31548378","citation_count":89,"is_preprint":false},{"pmid":"15060165","id":"PMC_15060165","title":"Homeobox protein MSX2 acts as a molecular defense mechanism for preventing ossification in ligament fibroblasts.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15060165","citation_count":88,"is_preprint":false},{"pmid":"9256341","id":"PMC_9256341","title":"Miz1, a novel zinc finger transcription factor that interacts with Msx2 and enhances its affinity for DNA.","date":"1997","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9256341","citation_count":87,"is_preprint":false},{"pmid":"17516553","id":"PMC_17516553","title":"Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17516553","citation_count":84,"is_preprint":false},{"pmid":"10451362","id":"PMC_10451362","title":"The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10451362","citation_count":83,"is_preprint":false},{"pmid":"18487199","id":"PMC_18487199","title":"Msx2 exerts bone anabolism via canonical Wnt signaling.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18487199","citation_count":81,"is_preprint":false},{"pmid":"7649547","id":"PMC_7649547","title":"Gene defect in hypodontia: exclusion of MSX1 and MSX2 as candidate genes.","date":"1995","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7649547","citation_count":81,"is_preprint":false},{"pmid":"11807043","id":"PMC_11807043","title":"Msx2 is an immediate downstream effector of Pax3 in the development of the murine cardiac neural crest.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11807043","citation_count":79,"is_preprint":false},{"pmid":"17601530","id":"PMC_17601530","title":"Msx1 and Msx2 regulate survival of secondary heart field precursors and post-migratory proliferation of cardiac neural crest in the outflow tract.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17601530","citation_count":77,"is_preprint":false},{"pmid":"17030628","id":"PMC_17030628","title":"Bone morphogenetic protein-induced MSX1 and MSX2 inhibit myocardin-dependent smooth muscle gene transcription.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17030628","citation_count":75,"is_preprint":false},{"pmid":"15155529","id":"PMC_15155529","title":"Msx2 and necdin combined activities are required for smooth muscle differentiation in mesoangioblast stem cells.","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15155529","citation_count":75,"is_preprint":false},{"pmid":"11668602","id":"PMC_11668602","title":"Msx2 is a repressor of chondrogenic differentiation in migratory cranial neural crest cells.","date":"2001","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/11668602","citation_count":75,"is_preprint":false},{"pmid":"17878071","id":"PMC_17878071","title":"Msx2 -/- transgenic mice develop compound amelogenesis imperfecta, dentinogenesis imperfecta and periodental osteopetrosis.","date":"2007","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/17878071","citation_count":72,"is_preprint":false},{"pmid":"24549638","id":"PMC_24549638","title":"BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2.","date":"2014","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/24549638","citation_count":72,"is_preprint":false},{"pmid":"18667074","id":"PMC_18667074","title":"Msx1 and Msx2 are required for endothelial-mesenchymal transformation of the atrioventricular cushions and patterning of the atrioventricular myocardium.","date":"2008","source":"BMC developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18667074","citation_count":70,"is_preprint":false},{"pmid":"17875939","id":"PMC_17875939","title":"Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17875939","citation_count":70,"is_preprint":false},{"pmid":"18285513","id":"PMC_18285513","title":"Msx1 and Msx2 are functional interacting partners of T-box factors in the regulation of Connexin43.","date":"2008","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18285513","citation_count":69,"is_preprint":false},{"pmid":"10588826","id":"PMC_10588826","title":"PDX-1 and Msx-2 expression in the regenerating and developing pancreas.","date":"1999","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10588826","citation_count":69,"is_preprint":false},{"pmid":"9265625","id":"PMC_9265625","title":"Structure-function analysis of Msx2-mediated transcriptional suppression.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9265625","citation_count":68,"is_preprint":false},{"pmid":"21471203","id":"PMC_21471203","title":"Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21471203","citation_count":68,"is_preprint":false},{"pmid":"15272023","id":"PMC_15272023","title":"Necdin interacts with the Msx2 homeodomain protein via MAGE-D1 to promote myogenic differentiation of C2C12 cells.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15272023","citation_count":67,"is_preprint":false},{"pmid":"7893602","id":"PMC_7893602","title":"Regulation of the Msx2 homeobox gene during mouse embryogenesis: a transgene with 439 bp of 5' flanking sequence is expressed exclusively in the apical ectodermal ridge of the developing limb.","date":"1994","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/7893602","citation_count":67,"is_preprint":false},{"pmid":"25056439","id":"PMC_25056439","title":"Targeted reduction of vascular Msx1 and Msx2 mitigates arteriosclerotic calcification and aortic stiffness in LDLR-deficient mice fed diabetogenic diets.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25056439","citation_count":66,"is_preprint":false},{"pmid":"18349132","id":"PMC_18349132","title":"Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18349132","citation_count":65,"is_preprint":false},{"pmid":"26427715","id":"PMC_26427715","title":"MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling.","date":"2015","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26427715","citation_count":64,"is_preprint":false},{"pmid":"11763998","id":"PMC_11763998","title":"Antagonistic regulation of Dlx2 expression by PITX2 and Msx2: implications for tooth development.","date":"2001","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/11763998","citation_count":62,"is_preprint":false},{"pmid":"19407244","id":"PMC_19407244","title":"Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: role of Msx2 gene induction via Notch-RBP-Jk signaling.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19407244","citation_count":62,"is_preprint":false},{"pmid":"30033084","id":"PMC_30033084","title":"MSX2 Initiates and Accelerates Mesenchymal Stem/Stromal Cell Specification of hPSCs by Regulating TWIST1 and PRAME.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30033084","citation_count":61,"is_preprint":false},{"pmid":"19103190","id":"PMC_19103190","title":"Genetic interplays between Msx2 and Foxn1 are required for Notch1 expression and hair shaft differentiation.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19103190","citation_count":61,"is_preprint":false},{"pmid":"22071108","id":"PMC_22071108","title":"Msx1 and Msx2 promote meiosis initiation.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22071108","citation_count":58,"is_preprint":false},{"pmid":"15499554","id":"PMC_15499554","title":"Msx2 controls ameloblast terminal differentiation.","date":"2004","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15499554","citation_count":54,"is_preprint":false},{"pmid":"8660900","id":"PMC_8660900","title":"Regulated expression of homeobox genes Msx-1 and Msx-2 in mouse mammary gland development suggests a role in hormone action and epithelial-stromal interactions.","date":"1996","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8660900","citation_count":52,"is_preprint":false},{"pmid":"20440096","id":"PMC_20440096","title":"Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation.","date":"2010","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20440096","citation_count":51,"is_preprint":false},{"pmid":"22685265","id":"PMC_22685265","title":"TNFR1-activated reactive oxidative species signals up-regulate osteogenic Msx2 programs in aortic myofibroblasts.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22685265","citation_count":50,"is_preprint":false},{"pmid":"15131132","id":"PMC_15131132","title":"MINT, the Msx2 interacting nuclear matrix target, enhances Runx2-dependent activation of the osteocalcin fibroblast growth factor response element.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15131132","citation_count":50,"is_preprint":false},{"pmid":"12674336","id":"PMC_12674336","title":"Fibroblast growth factors lead to increased Msx2 expression and fusion in calvarial sutures.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12674336","citation_count":48,"is_preprint":false},{"pmid":"34507999","id":"PMC_34507999","title":"MSX2 safeguards syncytiotrophoblast fate of human trophoblast stem cells.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34507999","citation_count":46,"is_preprint":false},{"pmid":"21372128","id":"PMC_21372128","title":"Transcriptional repression in the Notch pathway: thermodynamic characterization of CSL-MINT (Msx2-interacting nuclear target protein) complexes.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21372128","citation_count":46,"is_preprint":false},{"pmid":"12766037","id":"PMC_12766037","title":"Microphthalmia resulting from MSX2-induced apoptosis in the optic vesicle.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12766037","citation_count":46,"is_preprint":false},{"pmid":"15300013","id":"PMC_15300013","title":"Msx-1 and Msx-2 in mammary gland development.","date":"2004","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/15300013","citation_count":45,"is_preprint":false},{"pmid":"10569470","id":"PMC_10569470","title":"Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours.","date":"1999","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/10569470","citation_count":43,"is_preprint":false},{"pmid":"9368026","id":"PMC_9368026","title":"Stimulus-selective inhibition of rat osteocalcin promoter induction and protein-DNA interactions by the homeodomain repressor Msx2.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9368026","citation_count":43,"is_preprint":false},{"pmid":"21465616","id":"PMC_21465616","title":"Msx1 and Msx2 in limb mesenchyme modulate digit number and identity.","date":"2011","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/21465616","citation_count":40,"is_preprint":false},{"pmid":"15198690","id":"PMC_15198690","title":"Alx4 and Msx2 play phenotypically similar and additive roles in skull vault differentiation.","date":"2004","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/15198690","citation_count":37,"is_preprint":false},{"pmid":"9207129","id":"PMC_9207129","title":"Gestational exposure to ethanol suppresses msx2 expression in developing mouse embryos.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9207129","citation_count":37,"is_preprint":false},{"pmid":"10879654","id":"PMC_10879654","title":"Craniofacial disorders caused by mutations in homeobox genes MSX1 and MSX2.","date":"2000","source":"Journal of craniofacial genetics and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10879654","citation_count":36,"is_preprint":false},{"pmid":"20934968","id":"PMC_20934968","title":"Enamel protein regulation and dental and periodontal physiopathology in MSX2 mutant mice.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20934968","citation_count":35,"is_preprint":false},{"pmid":"21465479","id":"PMC_21465479","title":"The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21465479","citation_count":35,"is_preprint":false},{"pmid":"19170109","id":"PMC_19170109","title":"Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19170109","citation_count":35,"is_preprint":false},{"pmid":"10831122","id":"PMC_10831122","title":"The homeobox genes MSX2 and MOX2 are candidates for regulating epithelial-mesenchymal cell interactions in the human placenta.","date":"2000","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/10831122","citation_count":34,"is_preprint":false},{"pmid":"18682398","id":"PMC_18682398","title":"MSX2 stimulates chondrocyte maturation by controlling Ihh expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18682398","citation_count":33,"is_preprint":false},{"pmid":"15803476","id":"PMC_15803476","title":"Ventral abdominal wall dysmorphogenesis of Msx1/Msx2 double-mutant mice.","date":"2005","source":"The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/15803476","citation_count":33,"is_preprint":false},{"pmid":"16513791","id":"PMC_16513791","title":"MSX2 promotes vaginal epithelial differentiation and wolffian duct regression and dampens the vaginal response to diethylstilbestrol.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16513791","citation_count":32,"is_preprint":false},{"pmid":"23145080","id":"PMC_23145080","title":"Initiation of early osteoblast differentiation events through the direct transcriptional regulation of Msx2 by FOXC1.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23145080","citation_count":32,"is_preprint":false},{"pmid":"36779631","id":"PMC_36779631","title":"CLU (clusterin) promotes mitophagic degradation of MSX2 through an AKT-DNM1L/Drp1 axis to maintain SOX2-mediated stemness in oral cancer stem cells.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36779631","citation_count":30,"is_preprint":false},{"pmid":"25601840","id":"PMC_25601840","title":"MSX2 in ameloblast cell fate and activity.","date":"2015","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25601840","citation_count":28,"is_preprint":false},{"pmid":"15567410","id":"PMC_15567410","title":"Structural analysis of the group II intron splicing factor CRS2 yields insights into its protein and RNA interaction surfaces.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15567410","citation_count":28,"is_preprint":false},{"pmid":"23382810","id":"PMC_23382810","title":"BMP-mediated functional cooperation between Dlx5;Dlx6 and Msx1;Msx2 during mammalian limb development.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23382810","citation_count":28,"is_preprint":false},{"pmid":"18000908","id":"PMC_18000908","title":"Syndromic craniosynostosis due to complex chromosome 5 rearrangement and MSX2 gene triplication.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/18000908","citation_count":28,"is_preprint":false},{"pmid":"16379013","id":"PMC_16379013","title":"Formation of the CRS2-CAF2 group II intron splicing complex is mediated by a 22-amino acid motif in the COOH-terminal region of CAF2.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16379013","citation_count":26,"is_preprint":false},{"pmid":"7726844","id":"PMC_7726844","title":"DNA binding and transcriptional properties of wild-type and mutant forms of the homeodomain protein Msx2.","date":"1995","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7726844","citation_count":26,"is_preprint":false},{"pmid":"17068080","id":"PMC_17068080","title":"Functional interactions between Dlx2 and lymphoid enhancer factor regulate Msx2.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17068080","citation_count":26,"is_preprint":false},{"pmid":"18786927","id":"PMC_18786927","title":"The Boston-type craniosynostosis mutation MSX2 (P148H) results in enhanced susceptibility of MSX2 to ubiquitin-dependent degradation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18786927","citation_count":25,"is_preprint":false},{"pmid":"27435625","id":"PMC_27435625","title":"Msx1 and Msx2 function together in the regulation of primordial germ cell migration in the mouse.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27435625","citation_count":25,"is_preprint":false},{"pmid":"12205674","id":"PMC_12205674","title":"Msx2 and p21(CIP1/WAF1) mediate the proapoptotic effects of bone morphogenetic protein-4 on ventricular zone progenitor cells.","date":"2002","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/12205674","citation_count":25,"is_preprint":false},{"pmid":"21499300","id":"PMC_21499300","title":"MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21499300","citation_count":25,"is_preprint":false},{"pmid":"16586351","id":"PMC_16586351","title":"Msx1 and Msx2 have shared essential functions in neural crest but may be dispensable in epidermis and axis formation in Xenopus.","date":"2006","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16586351","citation_count":24,"is_preprint":false},{"pmid":"16118513","id":"PMC_16118513","title":"Agonistic and antagonistic action of AP2, Msx2, Pax6, Prox1 AND Six3 in the regulation of Sox2 expression.","date":"2005","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/16118513","citation_count":24,"is_preprint":false},{"pmid":"12416537","id":"PMC_12416537","title":"Tgf-beta1, Tgf-beta2, Tgf-beta3 and Msx2 expression is elevated during frontonasal suture morphogenesis and during active postnatal facial growth.","date":"2002","source":"Orthodontics & craniofacial research","url":"https://pubmed.ncbi.nlm.nih.gov/12416537","citation_count":24,"is_preprint":false},{"pmid":"24715462","id":"PMC_24715462","title":"Msx1 and Msx2 act as essential activators of Atoh1 expression in the murine spinal cord.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24715462","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52694,"output_tokens":11183,"usd":0.162913,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21791,"output_tokens":5021,"usd":0.11724,"stage2_stop_reason":"end_turn"},"total_usd":0.280153,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"A Pro148His substitution in the MSX2 homeodomain (position 7 of the N-terminal arm) causes autosomal dominant craniosynostosis (Boston type) by enhancing DNA binding affinity of the homeodomain, acting as a gain-of-function mutation.\",\n      \"method\": \"Human genetic mapping, segregation analysis, identification of missense mutation exclusively in affected individuals; mouse Msx2 transcript localization to calvarial sutures by in situ hybridization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutation identification with genetic segregation replicated and functionally validated in multiple subsequent studies\",\n      \"pmids\": [\"8106171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Both wild-type and P148H mutant Msx2 specifically bind a high-affinity homeodomain DNA target and repress reporter gene transcription in a dose-dependent but DNA binding site-independent manner, establishing MSX2 as a transcriptional repressor.\",\n      \"method\": \"Co-transfection reporter assays in cell lines, EMSA/DNA-binding assays with recombinant proteins\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (EMSA + reporter assay) in a single study\",\n      \"pmids\": [\"7726844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MSX-1 and MSX-2 share a common consensus DNA binding site but MSX-2 has higher apparent DNA-binding affinity; both function as transcriptional repressors independently of their consensus DNA binding sites; the distinction in repressor potency maps to sequences N-terminal to the homeodomain.\",\n      \"method\": \"DNA binding site selection, EMSA, luciferase reporter transcription assays with deletion mutants\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical assays (EMSA, reporter, deletion analysis), single lab\",\n      \"pmids\": [\"8861098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The core suppressor domain of Msx2 maps to residues 97–208, with residues 132–148 (upstream of and overlapping the homeodomain N-terminal extension) being essential; transcriptional suppression of the osteocalcin promoter does not require direct DNA binding by Msx2. Msx2 binds both subunits of TFIIF (RAP74 and RAP30) through its core suppressor domain; overexpression of RAP74 partially reverses Msx2-mediated suppression.\",\n      \"method\": \"Systematic N- and C-terminal and internal deletion mutagenesis with luciferase reporter assays in MC3T3-E1 osteoblasts; Far-Western blotting with recombinant proteins; co-transfection rescue experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis, multiple orthogonal methods, functional validation in relevant cell type\",\n      \"pmids\": [\"9265625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Msx2 suppresses FGF2/cAMP-stimulated but not calcitriol-stimulated osteocalcin promoter activity; mechanistically, Msx2 inhibits binding of the OCFRE-binding protein (OCFREB) to the FGF2-response element (OCFRE) via its core suppressor residues 132–148, without itself binding the OCFRE.\",\n      \"method\": \"Luciferase reporter assays in MC3T3-E1 osteoblasts with FGF2/forskolin or calcitriol stimulation; EMSA with recombinant GST-Msx2 and nuclear extracts; protein purification of OCFREB; deletion-mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified protein, mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"9368026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Miz1, a zinc-finger protein identified by yeast two-hybrid screen, directly interacts with Msx2 in vitro, enhances its DNA binding affinity for the osteocalcin promoter, and augments the effect of the P148H craniosynostosis mutation on DNA binding.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro protein interaction assays, EMSA with Msx2 and Miz1, Northern blot and in situ hybridization for expression overlap\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus in vitro binding and EMSA, single lab\",\n      \"pmids\": [\"9256341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Constitutive ectopic Msx2 expression induces apoptosis in aggregated P19 cells, and BMP4 induces cell death via an Msx2-dependent pathway; BMP4 treatment of P19 cells induces Msx2 transcription, placing Msx2 downstream of BMP4 in programmed cell death.\",\n      \"method\": \"Stable transfection of P19 cells with Msx2 expression construct; BMP4 treatment; apoptosis quantification; Msx2 mRNA induction assay\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function/gain-of-function with defined apoptosis phenotype, pathway positioning by BMP4-Msx2 epistasis, single lab\",\n      \"pmids\": [\"9205134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MINT (Msx2-interacting nuclear target protein) was identified as a direct binding partner of Msx2; the interaction requires Msx2 residues necessary for transcriptional suppression; MINT's N-terminal RRM domain selectively binds the G/T-rich OCFRE in the osteocalcin promoter; MINT co-segregates with Msx2 in chromatin/nuclear matrix fractions.\",\n      \"method\": \"Far-Western expression cloning with radiolabeled GST-Msx2 fusion; Farwestern analysis; EMSA with MINT RRM domain; cellular fractionation and co-sedimentation with topoisomerase II; transient transfection reporter assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods including Far-Western, EMSA, fractionation, reporter assay, all in one rigorous study\",\n      \"pmids\": [\"10451362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Overexpression of Msx2 in primary chick calvarial osteoblasts prevents osteoblast differentiation and matrix mineralization; antisense Msx2 decreases proliferation and accelerates differentiation; Msx2 promoter activity is downregulated in differentiating osteoblastic nodules, indicating Msx2 maintains osteoprogenitors in a proliferative, undifferentiated state.\",\n      \"method\": \"Retroviral-mediated sense and antisense Msx2 overexpression in primary calvarial osteoblasts; mineralization and differentiation marker assays; Msx2 promoter-reporter analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with defined cellular phenotype, single lab\",\n      \"pmids\": [\"10328922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Msx2 gene dosage controls the number of proliferative osteogenic cells in calvarial sutures; tissue-specific Msx2 overexpression in suture mesenchymal cells enhances parietal bone growth and increases BrdU-labeling of osteoblastic cells at the osteogenic front, consistent with a transient retardation of osteogenic cell differentiation.\",\n      \"method\": \"Transgenic mouse overexpression with Msx2-specific suture promoter; BrdU proliferation assay; histological analysis of cranial sutures\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model with proliferation quantification, single lab\",\n      \"pmids\": [\"9917362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Heterozygous loss-of-function mutations in the MSX2 homeodomain (RK159-160del and R172H) cause >85% reduction in DNA binding and produce parietal foramina via haploinsufficiency, demonstrating that MSX2 dosage is critical for calvarial ossification; in contrast, the gain-of-function P148H mutation that enhances DNA binding causes craniosynostosis.\",\n      \"method\": \"Human genetic mutation identification; in vitro DNA binding assays with mutant Msx2 proteins; mouse phenotype analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct DNA-binding biochemistry plus human genetics plus mouse phenotype, replicated across studies\",\n      \"pmids\": [\"10742103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Msx2-deficient mice have defective proliferation of osteoprogenitors at the calvarial osteogenic front; Msx2 is required for both chondrogenesis and osteogenesis in axial and appendicular skeleton, operating downstream of Pth/Pthrp receptor signaling; Msx1/Msx2 genetic dosage interactions modify PFM phenotype, indicating functional overlap.\",\n      \"method\": \"Msx2 null mutant mouse phenotyping; BrdU labeling; in situ hybridization for marker genes; Msx1/Msx2 compound mutant analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse with defined cellular phenotype, BrdU proliferation assay, epistasis analysis, replicated across multiple tissues\",\n      \"pmids\": [\"10742104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pax3 represses Msx2 expression via a direct effect on a conserved Pax3-binding site in the Msx2 promoter; in Splotch (Pax3-null) mutant mice, upregulation of Msx2 causes the deficiency in cardiac neural crest development, establishing Msx2 as an immediate downstream effector of Pax3.\",\n      \"method\": \"Genetic epistasis (Splotch mutant × Msx2 mutant compound mice); molecular analysis of Pax3 binding to Msx2 promoter; in situ hybridization\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis plus direct promoter-binding evidence, multi-approach single lab\",\n      \"pmids\": [\"11807043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Msx2 promotes osteogenic and suppresses adipogenic differentiation of mesenchymal progenitors; osteogenic actions require intrinsic DNA binding (gain-of-function P148H enhances mineralization; DNA-binding-deficient T147A is inactive for osteogenesis); suppression of adipogenesis does not require DNA binding but occurs via protein-protein interactions with C/EBPalpha controlling PPARgamma transcription.\",\n      \"method\": \"Viral transduction of Msx2 variants (wild-type, P148H, T147A) in C3H10T1/2 and aortic myofibroblast cells; alkaline phosphatase assay; mineralized nodule quantification; adipogenesis assays; C/EBPalpha interaction studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — structure-function mutagenesis distinguishing two mechanistic modes (DNA-binding-dependent vs. protein-protein interaction), multiple orthogonal readouts\",\n      \"pmids\": [\"12925529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Smad4 and Lef1 cooperatively activate the Msx2 promoter in response to BMP2; Wnt/beta-catenin signaling activates Msx2 via Lef1 binding and synergizes with BMP2; Wnt-dependent Msx2 activation requires Smad4 (not Smad1) even in the absence of BMP autocrine loops, demonstrated by chromatin immunoprecipitation showing Smad4 in the Lef1 transcriptional complex.\",\n      \"method\": \"Msx2 promoter-reporter assays; mutagenesis of Smad-binding elements and Lef1/TCF sites; Smad4-deficient ES cells; chromatin immunoprecipitation; co-transfection with Smad1, Smad4, and Lef1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter dissection with mutagenesis, ChIP, genetic loss-of-function (Smad4-null cells), multiple orthogonal methods\",\n      \"pmids\": [\"14551209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Msx2 occupies the osteocalcin gene promoter in proliferating (undifferentiated) osteoblasts and represses it; after proliferation, Msx2 is replaced by Dlx3, Dlx5, and Runx2, forming a molecular switch for osteocalcin transcriptional activation during osteoblast differentiation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) across stages of osteoblast differentiation; RNA interference knockdown of Dlx3; overexpression experiments; RNA polymerase II ChIP\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — sequential ChIP demonstrating temporal protein-DNA occupancy switch at endogenous locus across differentiation stages\",\n      \"pmids\": [\"15456894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Msx2 suppresses BMP2-induced alkaline phosphatase (ALP) expression by competing with Dlx5 for the same cis-acting element in the ALP promoter; high Msx2 levels counteract Dlx5-stimulated ALP transcription until the Dlx5:Msx2 ratio exceeds a threshold.\",\n      \"method\": \"ALP promoter dissection with EMSA and site-directed mutagenesis; Msx2 overexpression in C2C12 and Runx2(-/-) cells; ALP mRNA and enzyme activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter mutagenesis, EMSA demonstrating competitive binding, functional reporter assay, single lab\",\n      \"pmids\": [\"15383550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Msx2 colocalizes with Runx2/Osf2 and suppresses Runx2 transcriptional activity cooperatively with TLE1, recruiting HDAC1 activity to inhibit osteoblast differentiation in ligament fibroblasts; stable Msx2 knockdown in PDL-L2 cells induces osteoblastic differentiation and matrix mineralization.\",\n      \"method\": \"Co-immunoprecipitation; co-localization studies; RNA interference; stable overexpression in MC3T3-E1 cells; in situ hybridization; RT-PCR\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, loss-of-function and gain-of-function with defined mineralization phenotype, HDAC recruitment assay\",\n      \"pmids\": [\"15060165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MINT interacts functionally with Runx2 to enhance OCFRE-driven osteocalcin transcription; Msx2 abrogates Runx2-MINT activation by selectively inhibiting Runx2 binding to OC chromatin (demonstrated by ChIP); MINT adopts a reticular nuclear matrix distribution co-localizing with phospho-RNA polymerase II.\",\n      \"method\": \"Luciferase reporter assays in MC3T3E1 and CV1 cells; confocal immunofluorescence microscopy; chromatin immunoprecipitation; MINT RNA interference\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP showing Msx2 inhibits Runx2 chromatin binding, confocal localization, reporter reconstitution, multiple methods\",\n      \"pmids\": [\"15131132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Necdin associates with Msx2 via MAGE-D1; a ternary complex of necdin, MAGE-D1, and Msx2 forms in vitro and is detected as an endogenous complex in differentiating embryonal carcinoma cells; co-expression of necdin and MAGE-D1 relieves Msx2-dependent transcriptional repression and rescues Msx2-inhibited myogenic differentiation in C2C12 cells.\",\n      \"method\": \"In vitro binding assays; co-immunoprecipitation; stable transfection of C2C12 with Msx2; rescue co-expression experiments; differentiation marker assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro binding, endogenous Co-IP, functional rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15272023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Msx2 inhibits transcriptional activity of PPARgamma, C/EBPbeta, and C/EBPdelta, blocking adipocyte differentiation induced by overexpression of each; and promotes osteoblast differentiation independently of Runx2 (active in Runx2-null cells).\",\n      \"method\": \"Overexpression and reporter assays in C3H10T1/2, C2C12, 3T3-F442A, and Runx2(-/-) mesenchymal cells; alkaline phosphatase and adipogenesis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell line contexts, multiple differentiation readouts, single lab\",\n      \"pmids\": [\"15175325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Msx2-expressing cells secrete paracrine Wnt signals (upregulating Wnt3a and Wnt7a, downregulating Dkk1) that promote osteogenic and suppress adipogenic differentiation; Msx2 induces nuclear beta-catenin accumulation and TCF/LEF transcriptional activity; Dkk1 treatment reverses these effects; in vivo, TOPGAL reporter mice confirm augmented Wnt signaling in Msx2-transgenic aorta.\",\n      \"method\": \"Conditioned media transfer experiments; TCF/LEF reporter (TOPGAL) transgenic mice; immunofluorescence for nuclear beta-catenin; alkaline phosphatase assay; Dkk1 rescue; qRT-PCR for Wnt ligands\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditioned media, in vivo reporter mouse, multiple orthogonal methods, mechanistic rescue with Dkk1\",\n      \"pmids\": [\"15841209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Msx1 and Msx2 form a ternary complex with SRF and myocardin, inhibiting SRF/myocardin binding to the CArG-box motif and suppressing smooth muscle cell marker gene (SM22alpha, caldesmon) transcription; this interaction is induced downstream of BMP2/4/6 signaling.\",\n      \"method\": \"Co-immunoprecipitation; gel-shift (EMSA); chromatin immunoprecipitation; promoter-reporter assays; BMP treatment of VSMCs\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP, EMSA, ChIP, and reporter assay demonstrating ternary complex inhibiting CArG-box binding\",\n      \"pmids\": [\"17030628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Msx2 is a direct transcriptional target of Notch/RBP-Jk signaling; Notch1 intracellular domain (N1-ICD) induces Msx2 gene expression via an RBP-Jk-binding element within the Msx2 promoter; RBP-Jk-deficient cells fail to induce Msx2 in response to N1-ICD; Msx2 mediates N1-ICD-induced ALP activity and vascular smooth muscle cell mineralization.\",\n      \"method\": \"Msx2 promoter deletion and site-directed mutagenesis; RBP-Jk-deficient fibroblasts; siRNA knockdown of Msx2 and RBP-Jk; ALP activity assay; immunohistochemistry of human calcifying plaques\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter mutagenesis plus genetic loss-of-function (RBP-Jk-null cells) plus siRNA, three orthogonal approaches\",\n      \"pmids\": [\"19407244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Vitamin K2 (MK4) activates Msx2 gene transcription through PXR binding to a PXRE in the Msx2 promoter; ChIP shows PXR and p300 coactivator recruitment to this element; MK4-bound PXR cooperates with estrogen-bound ERalpha on the Msx2 promoter; knockdown of PXR or Msx2 attenuates MK4-induced osteoblast differentiation.\",\n      \"method\": \"2D-SDS-PAGE proteomics; Msx2 promoter reporter mapping; ChIP for PXR and p300; siRNA knockdown; co-transfection of PXR/RXRalpha/ERalpha\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP plus promoter mapping plus siRNA, multiple orthogonal methods establishing PXR as direct Msx2 transcriptional activator\",\n      \"pmids\": [\"17875939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMP2 regulates Osterix via two parallel pathways: a Runx2-dependent pathway and a Runx2-independent pathway through Msx2; Msx2 (induced by BMP2 in Runx2-null cells via Smad1/Smad4) induces Osterix expression; Msx2 knockdown inhibits BMP2-induced Osterix in Runx2-null cells.\",\n      \"method\": \"Runx2-deficient mesenchymal cells; Msx2 overexpression and siRNA knockdown; BMP2 treatment; Osterix and ALP expression assays; Smad overexpression/inhibitory Smad experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Runx2-null genetic background clarifies pathway, gain and loss of function, multiple readouts, single lab with strong controls\",\n      \"pmids\": [\"18703512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Msx2 exerts bone anabolic effects by reducing Dkk1 expression and enhancing canonical Wnt (Wnt7a, Wnt7b) signaling; Msx2 inhibits Dkk1 promoter activity and reduces RNA polymerase II association with Dkk1 chromatin; RNAi knockdown of Wnt7a, Wnt7b, and LRP6 significantly reduces Msx2-induced alkaline phosphatase; confirmed in Msx2-transgenic mice using TOPGAL reporter.\",\n      \"method\": \"CMV-Msx2 transgenic mice; microCT; histomorphometry; TOPGAL Wnt reporter; Msx2 siRNA; ChIP for RNA Pol II at Dkk1; Wnt7a/7b/LRP6 knockdown with rescue assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic with TOPGAL reporter, ChIP, systematic siRNA epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"18487199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Msx1 and Msx2 bind cardiac T-box proteins Tbx2, Tbx3, and Tbx5 via their homeodomain and T-box domains; Msx proteins together with Tbx2/Tbx3 suppress Connexin43 (Cx43) promoter activity; Msx1 binds the Cx43 promoter at a conserved site adjacent to a T-box site (by ChIP), and Msx activity on the Cx43 promoter depends on the presence of Tbx3.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro pull-down; reporter assays in rat heart-derived cells; chromatin immunoprecipitation\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid plus pulldown plus ChIP plus reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"18285513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Msx2 promotes chondrocyte maturation in part by upregulating Ihh (Indian hedgehog) expression; cyclopamine (hedgehog pathway inhibitor) blocks Msx2-induced chondrogenesis; Msx2's chondrogenic action requires BMP2/Smad signaling (Smad1/4 enhance, Smad6 blocks).\",\n      \"method\": \"Overexpression of constitutively active Msx2 in primary chondrocytes and metatarsal explants; cyclopamine treatment; Smad overexpression/inhibition; ALP and collagen X expression assays; Msx2 siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with pharmacological rescue, single lab, multiple assays\",\n      \"pmids\": [\"18682398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The Boston craniosynostosis P148H mutation renders MSX2 more susceptible to ubiquitin-dependent proteasomal degradation; Praja1 E3 ubiquitin ligase mediates MSX2 degradation; P148H shows greater ubiquitylation and shorter protein half-life than wild-type; P148H functions as a dominant-negative by increasing ubiquitylation of wild-type MSX2.\",\n      \"method\": \"Pulse-chase protein half-life experiments; ubiquitylation assays; Praja1 co-expression; dominant-negative co-expression; osteoblast proliferation and cyclin D1 assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — pulse-chase, ubiquitylation assay, E3 ligase identification, dominant-negative mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"18786927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMP4-induced EMT in pancreatic cancer cells requires MSX2; BMP4 induces MSX2 via ERK, p38 MAPK, and Smad pathways; siRNA-mediated MSX2 knockdown abolishes BMP4-induced E-cadherin repression, vimentin induction, and enhanced cell migration.\",\n      \"method\": \"BMP4 treatment of Panc-1 cells; MSX2 siRNA knockdown; pathway inhibitors (ERK, p38, Smad); migration assays; Western blot for EMT markers\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis plus pathway inhibitor rescue, single lab, multiple EMT readouts\",\n      \"pmids\": [\"17516553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Msx2 mediates TNF-alpha inhibition of BMP2-induced osteoblast differentiation; TNF-alpha induces Msx2 via NF-kappaB pathway (not JNK); Msx2 siRNA rescues ALP expression suppressed by TNF-alpha, placing Msx2 as a downstream effector of TNF-alpha/NF-kappaB in inhibiting osteogenesis.\",\n      \"method\": \"TNF-alpha treatment of C2C12 and Runx2(-/-) calvarial cells; pathway-specific inhibitors for NF-kappaB and JNK; Msx2 siRNA knockdown; ALP expression assays\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis plus pharmacological pathway inhibitors, single lab\",\n      \"pmids\": [\"20440096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF acts through TNFR1 (not TNFR2) to upregulate Msx2 via reactive oxygen species (ROS) generated by NADPH oxidase (Nox); hydrogen peroxide directly upregulates Msx2 mRNA and promoter activity; Nox inhibition, p47phox genetic deficiency, and rotenone reduce TNF-induced Msx2; TNFR1-null aortic myofibroblasts express ~5% of wild-type Msx2 and are non-inducible by TNF.\",\n      \"method\": \"TNFR1-/- and TNFR2-/- cells; p47phox-/- cells; Nox inhibitors; H2O2 treatment; Msx2 promoter reporter; antisense oligonucleotides in SM22-TNF transgenic mice\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic knockouts, pharmacological inhibition, reporter assay, in vivo validation, orthogonal approaches\",\n      \"pmids\": [\"22685265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Notch signaling (N1-ICD/RBP-Jk) enhances BMP2-responsiveness of the Msx2 promoter; Smad1 interacts with N1-ICD to form a complex within the Msx2 promoter; RBP-Jk binding element is required for this synergistic BMP2 + Notch induction of Msx2 gene expression and subsequent ALP activity/mineralization in smooth muscle cells.\",\n      \"method\": \"Msx2 promoter deletion/mutation analysis; RBP-Jk-deficient cells; siRNA for RBP-Jk; co-immunoprecipitation of Smad1 and N1-ICD; ChIP at Msx2 promoter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter mutagenesis, genetic loss-of-function (RBP-Jk null), Co-IP demonstrating Smad1-N1-ICD complex on Msx2 promoter, ChIP\",\n      \"pmids\": [\"21471203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MSX2 directly regulates ABCG2 transcription in functional cooperation with SP1 via SP1-binding elements within the ABCG2 promoter; MSX2 overexpression or siRNA knockdown proportionally changes ABCG2 expression, and MSX2 expression correlates with chemoresistance.\",\n      \"method\": \"ABCG2 promoter reporter assay with MSX2 and SP1 co-expression; siRNA knockdown; overexpression; correlation of MSX2 and ABCG2 mRNA levels across cell lines\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter plus gain/loss-of-function, single lab\",\n      \"pmids\": [\"21465479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FOXC1 directly occupies a conserved element in the MSX2 promoter (by ChIP) and transcriptionally activates both human and mouse MSX2 promoters; FOXC1 siRNA reduces endogenous MSX2 expression; heterologous Foxc1 expression in C2C12 cells elevates ALP activity and Runx2 and Msx2 levels, placing FOXC1 upstream of MSX2 in early osteoblast differentiation.\",\n      \"method\": \"ChIP for FOXC1 at MSX2 promoter; luciferase reporter assays; siRNA; Foxc1 overexpression in C2C12\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus siRNA, single lab\",\n      \"pmids\": [\"23145080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Msx2 and Wnt7b signaling maintain aortic endothelial cell (EC) phenotype and oppose endothelial-mesenchymal transition (EndoMT); EC-specific deletion of Wnt7b upregulates osteogenic genes including Msx2 and nuclear phospho-Smad1/5; Msx2 in ECs has the opposite effect to mesenchymal cells, preserving EC identity.\",\n      \"method\": \"Cdh5-Cre;Wnt7b(fl/fl);LDLR(-/-) conditional knockout mice; adenoviral transduction of aortic ECs; immunofluorescence; Western blot; calcium/collagen quantification\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional EC-specific knockout with defined phenotype, single lab\",\n      \"pmids\": [\"23685555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MSX2 is a direct BMP pathway target in human pluripotent stem cells (hPSCs); MSX2 destabilizes pluripotency by directly binding the SOX2 promoter and repressing SOX2 transcription; simultaneously MSX2 directly activates Nodal promoter to commit cells to mesendoderm; SOX2 can promote MSX2 protein degradation, establishing mutual antagonism; Wnt signals via LEF1 synergistically activate MSX2 during mesendoderm induction.\",\n      \"method\": \"MSX2 overexpression and shRNA depletion in hPSCs; ChIP for MSX2 binding to SOX2 and Nodal promoters; promoter reporter assays; protein half-life measurement; MSX2/SOX2 co-expression\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP for direct promoter binding plus gain/loss-of-function, mutual protein-level antagonism demonstrated, multiple targets and mechanisms\",\n      \"pmids\": [\"26427715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MSX2 is a substrate of FBXW2 E3 ubiquitin ligase; FBXW2 binds MSX2, promotes its ubiquitylation and proteasomal degradation, and shortens its protein half-life; hypoxia induces VRK2 kinase to facilitate MSX2-FBXW2 binding and enhance FBXW2-mediated MSX2 degradation; MSX2 accumulation (upon FBXW2 inactivation) represses SOX2 transcription.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitylation assays; FBXW2 overexpression and siRNA knockdown with pulse-chase; VRK2 kinase assays; in vitro and in vivo breast cancer models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP, ubiquitylation assay, pulse-chase, kinase assay, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"31548378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MSX2 represses the syncytiotrophoblast transcriptional program in human trophoblast stem cells; MSX2 directly binds and regulates differentiation genes; MSX2 interacts with the SWI/SNF canonical BAF (cBAF) subcomplex and co-occupies target genes together with H3K27ac; MSX2 depletion increases H3K27ac and cBAF occupancy at differentiation genes, indicating MSX2 prevents chromatin remodeling at syncytiotrophoblast loci.\",\n      \"method\": \"MSX2 shRNA depletion and overexpression in human trophoblast stem cells; ChIP-seq for MSX2, H3K27ac, and cBAF components; immunoprecipitation-mass spectrometry for MSX2 interactors; transcriptomics\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-seq for direct binding, MS-identified complex, gain/loss-of-function, multiple orthogonal genome-wide methods\",\n      \"pmids\": [\"34507999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLU-mediated mitophagy promotes degradation of MSX2 in mitochondria/cytoplasm, preventing its nuclear translocation; when MSX2 is degraded by mitophagy, SOX2 expression is derepressed, maintaining cancer stemness; CLU activates AKT, which phosphorylates DNM1L/Drp1 at Ser616 to initiate mitochondrial fission preceding mitophagy of MSX2.\",\n      \"method\": \"CLU gain/loss-of-function in oral CSCs; MSX2 nuclear vs. cytoplasmic fractionation; mitophagy assays; AKT inhibition; DNM1L phosphorylation assays; SOX2 reporter/expression assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation demonstrating mitophagy-dependent nuclear exclusion, AKT-DNM1L pathway, single lab\",\n      \"pmids\": [\"36779631\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MSX2 is a homeodomain transcriptional repressor that controls osteogenic, adipogenic, chondrogenic, and cell fate decisions downstream of BMP2/4/Smad, Wnt/beta-catenin, Notch/RBP-Jk, TNF/TNFR1/ROS, and FGF signaling; it represses gene transcription through a core suppressor domain (residues 97–208, critical residues 132–148) via protein-protein interactions with TFIIF (RAP74), Runx2 (recruiting TLE1/HDAC1), MINT, myocardin/SRF, C/EBPalpha, and the cBAF SWI/SNF complex, largely independently of direct DNA binding; promotes osteogenesis in part by suppressing Dkk1 and upregulating Wnt7a/Wnt7b for paracrine Wnt signaling; its protein stability is regulated by FBXW2-mediated ubiquitylation/proteasomal degradation (enhanced by VRK2-facilitated FBXW2 binding) and by mitophagic degradation downstream of CLU/AKT/DNM1L; gain-of-function (P148H) causes craniosynostosis by enhancing DNA-binding affinity while also increasing proteasomal susceptibility, and haploinsufficiency causes parietal foramina, demonstrating strict dosage requirements for calvarial morphogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MSX2 is a homeodomain transcriptional repressor that acts as a dosage-sensitive node integrating BMP, Wnt, Notch, FGF, and TNF signals to control osteogenic, adipogenic, chondrogenic, and broader cell-fate decisions [#13, #21, #23]. It represses transcription largely independently of direct DNA binding through a core suppressor domain (residues 97\\u2013208, with residues 132\\u2013148 essential) that engages the basal machinery and other regulators: it binds both subunits of TFIIF (RAP74/RAP30) [#3], blocks promoter occupancy of partner factors such as the OCFRE-binding protein and Runx2 [#4, #18], and cooperates with TLE1 to recruit HDAC1 to suppress Runx2-driven osteoblast differentiation [#17]. MSX2 maintains osteoprogenitors in a proliferative, undifferentiated state\\u2014occupying the osteocalcin promoter until it is replaced by Dlx/Runx2 as a differentiation switch [#15]\\u2014and competes with Dlx5 and inhibits adipogenic factors PPAR\\u03b3 and C/EBP\\u03b1 through protein\\u2013protein interaction, biasing mesenchymal progenitors toward bone over fat [#13, #16, #20]. Its bone-anabolic output is amplified by paracrine canonical Wnt signaling: MSX2 represses Dkk1 and induces Wnt7a/Wnt7b to drive \\u03b2-catenin/TCF activity [#21, #26]. Beyond the skeleton, MSX2 represses pluripotency and lineage programs by directly binding promoters\\u2014repressing SOX2 while activating Nodal in mesendoderm commitment [#37]\\u2014and prevents cBAF-dependent chromatin remodeling at syncytiotrophoblast differentiation genes [#39]. MSX2 protein abundance is tightly controlled by FBXW2-mediated ubiquitin\\u2013proteasomal degradation, enhanced by hypoxia-induced VRK2, and by CLU/AKT/DNM1L-driven mitophagic clearance that excludes it from the nucleus to derepress SOX2 [#38, #40]. Gain-of-function P148H enhances homeodomain DNA-binding affinity to cause Boston-type craniosynostosis while paradoxically increasing proteasomal susceptibility, and homeodomain loss-of-function mutations cause parietal foramina by haploinsufficiency, establishing strict gene-dosage requirements for calvarial morphogenesis [#0, #10, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established MSX2 as a disease gene by linking a homeodomain point mutation to a calvarial malformation, framing the question of how a transcription factor controls suture morphogenesis.\",\n      \"evidence\": \"Human genetic mapping and segregation of the P148H missense allele, with mouse calvarial in situ localization\",\n      \"pmids\": [\"8106171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the molecular mechanism of repression\", \"Left open how enhanced DNA binding translates to premature suture fusion\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined MSX2's biochemical activity as a transcriptional repressor that acts independently of its consensus DNA-binding site, with repressor potency mapping outside the homeodomain.\",\n      \"evidence\": \"DNA-binding site selection, EMSA, and luciferase reporter assays with deletion mutants in cell lines\",\n      \"pmids\": [\"7726844\", \"8861098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the protein partners mediating DNA-binding-independent repression\", \"Endogenous target genes not defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapped the core suppressor domain and identified its first mechanistic basis\\u2014engagement of the basal transcription factor TFIIF\\u2014explaining DNA-binding-independent repression.\",\n      \"evidence\": \"Systematic deletion mutagenesis with osteoblast reporter assays, Far-Western binding, and RAP74 rescue, plus blocking of OCFREB binding to the FGF-response element\",\n      \"pmids\": [\"9265625\", \"9368026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not show TFIIF interaction at endogenous loci by ChIP\", \"Did not establish which signaling inputs deploy the suppressor domain\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified nuclear protein partners (MINT, Miz1) and positioned MSX2 as a brake on osteoblast differentiation that keeps progenitors proliferative.\",\n      \"evidence\": \"Far-Western expression cloning, yeast two-hybrid, EMSA, fractionation, and reciprocal gain/loss-of-function in calvarial osteoblasts\",\n      \"pmids\": [\"10451362\", \"9256341\", \"10328922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction stoichiometry and complex architecture unresolved\", \"Whether MINT and Miz1 act on the same target promoters not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved the dosage logic of MSX2 in the skull by contrasting gain-of-function craniosynostosis with loss-of-function parietal foramina.\",\n      \"evidence\": \"Human mutation identification with in vitro DNA-binding assays and Msx2-null mouse phenotyping including BrdU and epistasis with Msx1\",\n      \"pmids\": [\"10742103\", \"10742104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets governing osteoprogenitor proliferation not enumerated\", \"Mechanism of Msx1/Msx2 functional redundancy at the molecular level unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Distinguished two mechanistic modes of MSX2 action\\u2014DNA-binding-dependent pro-osteogenic versus protein-interaction-dependent anti-adipogenic\\u2014and placed it downstream of BMP2/Wnt via Smad4/Lef1 promoter activation.\",\n      \"evidence\": \"Structure-function mutagenesis (P148H, T147A) in mesenchymal cells, C/EBP\\u03b1 interaction studies, and Msx2 promoter dissection with ChIP in Smad4-null cells\",\n      \"pmids\": [\"12925529\", \"14551209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single protein switches between the two modes in vivo not defined\", \"Direct osteogenic DNA targets requiring binding not identified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined MSX2 as the repressive arm of a temporal molecular switch at osteoblast promoters, acting via competition with Dlx5/Runx2 and recruitment of TLE1/HDAC1.\",\n      \"evidence\": \"Stage-resolved ChIP at osteocalcin, EMSA competition at the ALP promoter, Co-IP and HDAC recruitment assays, and ternary complexes with necdin/MAGE-D1 and Runx2/MINT\",\n      \"pmids\": [\"15456894\", \"15383550\", \"15060165\", \"15131132\", \"15175325\", \"15272023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative thresholds for the Dlx5:Msx2 switch in vivo not established\", \"Generality of HDAC1/TLE1 recruitment across MSX2 targets untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed MSX2 acts non-cell-autonomously through secreted Wnt ligands and Dkk1 repression to bias mesenchymal fate toward bone.\",\n      \"evidence\": \"Conditioned media transfer, TOPGAL reporter mice, nuclear \\u03b2-catenin imaging, and Dkk1 rescue\",\n      \"pmids\": [\"15841209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Wnt ligand induction is direct transcriptional activation by MSX2 not shown here\", \"Receiving cell populations in vivo not fully defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Expanded MSX2's regulatory inputs (Notch/RBP-Jk, PXR, BMP2/Smad in Runx2-null context) and outputs (Osterix, Ihh, smooth-muscle and cardiac genes), and revealed proteasomal control of the protein.\",\n      \"evidence\": \"Promoter mutagenesis with RBP-Jk-null cells, ChIP for PXR/p300, Runx2-null epistasis for Osterix, T-box partner pulldowns, and pulse-chase/ubiquitylation with Praja1 E3 ligase\",\n      \"pmids\": [\"19407244\", \"17875939\", \"18703512\", \"18682398\", \"18285513\", \"17030628\", \"18786927\", \"17516553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How distinct upstream signals select between activation and repression outputs unresolved\", \"Physiological relevance of Praja1-mediated turnover in vivo not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a TNF\\u2192TNFR1\\u2192Nox/ROS axis driving MSX2 to inhibit osteogenesis and demonstrated Notch\\u2013BMP synergy at the MSX2 promoter via a Smad1\\u2013N1ICD complex.\",\n      \"evidence\": \"TNFR1/TNFR2 and p47phox knockouts, Nox inhibitors, H2O2 promoter assays, and Co-IP/ChIP at the Msx2 promoter\",\n      \"pmids\": [\"22685265\", \"21471203\", \"20440096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream osteogenic targets repressed by ROS-induced MSX2 not enumerated\", \"Cell-type specificity of the ROS input not generalized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Generalized MSX2 to stem-cell fate control as a direct repressor of SOX2 and activator of Nodal, establishing mutual MSX2\\u2013SOX2 antagonism at both transcript and protein levels.\",\n      \"evidence\": \"ChIP for direct promoter binding, gain/loss-of-function in hPSCs, and protein half-life measurements\",\n      \"pmids\": [\"26427715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-factors at the SOX2 and Nodal promoters not identified\", \"Mechanism of SOX2-driven MSX2 protein destabilization unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected MSX2 repression to chromatin remodeling control, showing it restrains cBAF/H3K27ac at differentiation loci, and identified cBAF as a physical interactor.\",\n      \"evidence\": \"ChIP-seq for MSX2/H3K27ac/cBAF, IP-MS for interactors, and gain/loss-of-function in human trophoblast stem cells\",\n      \"pmids\": [\"34507999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MSX2 directly antagonizes cBAF recruitment or via intermediaries not resolved\", \"Generality of cBAF antagonism beyond trophoblast loci untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a second post-translational control layer: mitophagic degradation of MSX2 via CLU/AKT/DNM1L excludes it from the nucleus to derepress SOX2 and sustain cancer stemness.\",\n      \"evidence\": \"CLU gain/loss-of-function, nuclear/cytoplasmic fractionation, mitophagy assays, AKT inhibition and DNM1L phosphorylation assays in oral cancer stem cells\",\n      \"pmids\": [\"36779631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How nuclear MSX2 is routed to mitochondria for mitophagy mechanistically unclear\", \"Single-lab finding awaiting independent confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how MSX2 dynamically selects between its repressor and activator outputs and between DNA-binding-dependent and -independent modes in response to distinct upstream signals at the level of a unified molecular mechanism.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of MSX2 bound to its co-repressors or to cBAF\", \"Genome-wide direct target catalogs across lineages incomplete\", \"Integration of transcriptional inputs with FBXW2/VRK2 and mitophagy degradation control not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 3, 13, 15, 37, 39]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 10, 13, 37]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [37, 39]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 18, 40]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [40]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 13, 15, 37, 39]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 21, 23, 26, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 13, 28, 37]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [29, 38]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [17, 39]}\n    ],\n    \"complexes\": [\"cBAF (SWI/SNF)\"],\n    \"partners\": [\"RAP74 (GTF2F1)\", \"Runx2\", \"TLE1\", \"HDAC1\", \"MINT (SPEN)\", \"C/EBPalpha\", \"myocardin\", \"FBXW2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}